Targeting the RAS signalling pathway in cancer;Ciblage de la voie de signalisation RAS pour le traitement des cancers

Bulletin du Cancer

Volumn 98, Issue 9, 2011, Pages 1019-1028

  Mansi, Laura ^a   Viel, Erika ^a   Curtit, Elsa ^a   Medioni, Jacques ^b   Le Tourneau, Christophe ^c  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSTITUT CURIE   (France)

Author keywords

Colorectal cancer; Farnesyl transferase; Lung cancer; Molecularly targeted therapies; RAS

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; RAS PROTEIN;

ANGIOGENESIS; CELL CYCLE; CELL SURVIVAL; HUMAN; NEOPLASM; NONHUMAN; PROTEIN TARGETING; REVIEW;

EID: 80053490770     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1380     Document Type: Review

References (88)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3 : 11-22. (Pubitemid 37328883)
2. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002; 1602 : 23-45. (Pubitemid 34311898)
3. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993; 62 : 851-91. (Pubitemid 23237890)
4. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7 : 295-308. (Pubitemid 46480970)
5. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998; 17 : 1395-413. (Pubitemid 28458409)
6. Mitin N, Rossman K, Der CJ. Signalling interplay in Ras superfamily function. Curr Biol 2005; 15 : 563-74.
7. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 1995; 14 : 3136-45.
8. Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001; 171 : 1-10. (Pubitemid 32727350)
9. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994; 369 : 411-4. (Pubitemid 24184056)
10. Le Tourneau C, Faivre S, Serova M, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work. Br J Cancer 2008; 99 : 1197-203.
11. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33 : 392-406. (Pubitemid 44142735)
12. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370 : 527-32. (Pubitemid 24264918)
13. Smith SC, Theodorescu D. The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urol Oncol 2009; 27 : 42-7.
14. Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med 2006; 12 : 283-5. (Pubitemid 43355073)
15. Löhr M, Klöppel G, Maisonneuve P, Lowenfels AB, Lüttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005; 7 : 17-23. (Pubitemid 40209467)
16. Yordy JS, Muise-Helmericks RC. Signal transduction and the Ets family of transcription factors. Oncogene 2000; 19 : 6503-13. (Pubitemid 32108440)
17. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92 : 131-9. (Pubitemid 40188446)
18. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26 : 1626-34.
19. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005; 11 : 2875-8. (Pubitemid 40525186)
20. Bellacosa A, De Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64 : 280-5.
21. Cestac P, Doisneau-Sixou S, Favre G. Development of farsenyl transferase inhibitors as anticancer agents. Ann Pharm Fr 2005; 63 : 76-84. (Pubitemid 40292047)
22. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995; 8 : 792-7.
23. Faivre G. The mitogen activated protein kinases (MAPK), cible de stratégies tumorales. Bull Cancer 2006; 93 : 25-30.
24. Vrignaud P, Bissery MC, Mailliet P, Lavelle F. RPR 130401, a nonpeptidomimetic farnesyltransferase inhibitor with in vivo activity. Ann N Y Acad Sci 1999; 886 : 249-51. (Pubitemid 30042450)
25. Pei XY, Dai Y, Rahmani M, Li W, Dent P, Grant S. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 2005; 12 : 4589-600. (Pubitemid 40825650)
26. Kopec M, Strusinska K, Legat M, Makowski M, Jakobisiak M, Golab J. Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro. Oncol Rep 2004; 5 : 1127-31.
27. Girgert R, Wittrock J, Pfister S, Schweizer P. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF. J Cancer Res Clin Oncol 2003; 4 : 227-33. (Pubitemid 36713798)
28. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61 : 131-7. (Pubitemid 32095710)
29. Pan J, Yeung SC. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 2005; 20 : 9109-12. (Pubitemid 41507967)
30. Kurzrock R, Kantarjian HM, Blascovich MA, et al. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res 2008; 14 : 509-14. (Pubitemid 351226120)
31. Crul M, De Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002; 20 : 2726-35. (Pubitemid 34575646)
32. Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15 : 1187-93. (Pubitemid 39199305)
33. Rolland D, Ribrag V, Haioun C, et al. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Étude des Lymphomes de l'Adulte trial. Cancer Chemother Pharmacol 2009; 65 : 781-90.
34. Rosenberg JE, Von der Maase H, Seigne JD, et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005; 103 : 2035-41. (Pubitemid 40605110)
35. Whitehead RP, McCoy S, Macdonald JS, et al. Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. Invest New Drugs 2006; 24 : 335-41.
36. Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG 9924) study. Invest New Drugs 2005; 23 : 485-7. (Pubitemid 41160096)
37. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor R115777, in advanced breast cancer. J Clin Oncol 2003; 21 : 2492-9. (Pubitemid 46606330)
38. Adjei AA, Croghan GA, Erlichman C, et al. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2003; 9 : 2520-6. (Pubitemid 36842092)
39. van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22 : 1430-8. (Pubitemid 41103625)
40. Korycka A, Smolewski P, Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol 2004; 73 : 418-26. (Pubitemid 39564365)
41. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97 : 3361-9.
42. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007; 109 : 1387-94. (Pubitemid 46242109)
43. Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009; 114 : 1166-73.
44. Petit T, Izbicka E, Lawrence RA, Bishop WR, Weitman S, Von Hoff DD. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Ann Oncol 1999; 10 : 449-53. (Pubitemid 29236423)
45. Eskens FA, Awada A, Cutler DL, et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001; 19 : 1167-75. (Pubitemid 32176295)
46. Sharma S, Kemeny N, Kelsen DP, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 2002; 13 : 1067-71.
47. Winquist E, Moore MJ, Chi KN, et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005; 23 : 143-9. (Pubitemid 40720377)
48. Kim ES, Kies MS, Fossella FV, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 2005; 104 : 561-9. (Pubitemid 41022814)
49. Dempke WC. Farnesyltransferase inhibitors - a novel approach in the treatment of advanced pancreatic carcinomas. Anticancer Res 2003; 23 : 813-8. (Pubitemid 36750877)
50. Theodore C, Geoffrois L, Vermorken JB, et al. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005; 8 : 1150-7. (Pubitemid 40725573)
51. Buanes T, Bernhardt S, Lislerud K, et al. RAS peptide vaccination in resected pancreatic cancer patients-persistence of anti tumor response and long term survival. 2007 ASCO Annual Meeting Proceedings; 25 : 18S [abstract 4543].
52. Achtar MS, Toubaji A, Herrin V, et al. Phase II clinical trial of mutant Ras peptide vaccines in combination with GM-CSF and IL2 in advanced cancer patients. 2007 ASCO Annual Meeting Proceedings; 25 : 18S [abstract 3067].
53. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351 : 289-305.
54. Schwartz GK, Robertson S, Shen A, et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) woth advanced solid tumors. 2009 ASCO Annual Meeting Proceedings; 27 : 15S [abstract 3513].
55. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417 : 949-54. (Pubitemid 34716871)
56. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64 : 7099-109. (Pubitemid 39331023)
57. Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther 2008; 7 : 3509-18.
58. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98 : 326-34. (Pubitemid 43338212)
59. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356 : 125-34. (Pubitemid 46089673)
60. Albouy B, Gross Goupil M, Escudier B, Massard C. Renal cell carcinoma management and therapies in 2010. Bull Cancer 2010; 97 : 17-28.
61. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 : 378-90.
62. Taieb J, BArbare JC, Boussaha T, et al. Management of hepatocelular carcinoma. Where are we now? What's next? Bull Cancer 2009; 96 : 19-34.
63. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 17 : 2823-30.
64. Kolinsky KD, Su F, Bollag G, Lee R, Packman K, Schostack K. Efficacy of PLX4032, a selective V600E B-RAF inhibitor, as monotherapy or in combination with capecitabine±bevacizumab in a colorectal cancer xenograft model. 2009 Gastrointestinal Cancers Symposium [abstract 362].
65. Yang S, Ngo VC, Lew GB, et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther 2009; 9 : 2537-45.
66. Ciuffreda L, Del Bufalo D, Desideri M, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 2009; 11 : 720-31.
67. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26 : 2139-46.
68. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351 : 337-45. (Pubitemid 38944402)
69. Saltz LB, Meropol NJ, Loehrer Sr. PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22 : 1201-8. (Pubitemid 41079832)
70. van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25 : 1658-64. (Pubitemid 46797944)
71. van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. 2008 ASCO Annual Meeting Proceedings; 26 : 2S [abstract 2].
72. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357 : 2040-8. (Pubitemid 350106711)
73. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 : 3992-5.
74. Blons H, Laurent-Puig P. Technical considérations for KRAS testing in colorectal cancer. The biologist's point of view. Bull Cancer 2009; 96 : 47-56.
75. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26 : 374-9. (Pubitemid 351171687)
76. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27 : 2091-6.
77. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud G, Volovat C, Nippgen J. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. 2008 ASCO Annual Meeting Proceedings; 26 : 20S [abstract 4000].
78. Di Fiore F, Michel P. Prognostic role of KRAS mutation in colorectal cancer. Bull cancer 2009; 96 : 23-30.
79. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27 : 5924-30.
80. Razis E, Briasoulis E, Vrettou E, et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 2008; 8 : 234.
81. Italiano A, Follana P, Caroli FX, et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008; 15 : 649-54.
82. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 : 123-32. (Pubitemid 41058344)
83. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999; 17 : 668-75. (Pubitemid 29075256)
84. Lacroix L, Besse B, Bidart JM, Bosq J. KRAS status versus EGFR status in lung cancer therapy. Bull cancer 2009; 96 : 75-83.
85. Le Moulec S, Loriot Y, Soria JC. Targeting KRAS Pathway in NSCLC therapy. Bull Cancer 2009; 96 : 69-74.
86. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2009; 69 : 272-8.
87. O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from FLEX study. 2009 ASCO Annual Meeting Proceedings; 27 : 15S [abstract 8007].
88. Khambata-Ford S, Harbison C, Woytowitz D, et al. K-Ras mutation(mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial. 2009 ASCO Annual Meeting Proceedings; 27 : 15S [abstract 8021].